Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABBV 706

Next Previous
Drug Profile

ABBV 706

Alternative Names: ABBV-706

Latest Information Update: 30 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 22 Jan 2026 AbbVie plans a phase III trial for Small cell lung cancer (Second-line therapy or greater) (IV, Infusion) in April 2026 (NCT07365241)(EUCT2025-523819-11)
  • 30 Dec 2025 AbbVie initiates a expanded access program for ABBV 706 in Small cell lung cancer (In children, In adults and In elderly) (IV, Infusion) (NCT07310277)
  • 25 Nov 2025 Phase-II clinical trials in Small cell lung cancer (Combination therapy, First-line therapy) in Japan, Taiwan (IV) (NCT07155174)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top